Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics Revenues up, Losses Down in Q3 of FY2004

NEW YORK, April 27 (GenomeWeb News) - Celera Diagnostics reported increased revenues and smaller losses for the fiscal year 2004 third quarter today.

 

The company, a joint venture of Applied Biosystems and Celera Genomics, both units of Applera, had revenues of $7.5 million, up from $4.3 million during the same quarter last year.

 

R&D spending was $10.7 million, down from $11.7 million during the year-ago period.

 

Celera Diagnostics' net loss for the quarter decreased to $11.9 million, from $12.6 million during the same period last year.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.